nVerses Capital’s Cullinan Oncology CGEM Stock Holding History

nVerses Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-600	Closed	-$10K	–	161
2024 Q3	$10K	Buy	+600	New	+$10.6K	﹤0.01%	892

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

nVerses Capital's CGEM Position: Q4 2024 in Review

nVerses Capital sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 600 shares — an estimated $10K sold.

nVerses Capital first reported a position in CGEM in Q3 2024 and held it in 1 quarter. The position peaked at $10K in Q3 2024. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

nVerses Capital reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 600 Cullinan Oncology shares in Q4 2024, an estimated $10K.
nVerses Capital first reported a position in Cullinan Oncology in Q3 2024 and held it in 1 quarter.
nVerses Capital's Cullinan Oncology position peaked at $10K in Q3 2024.
146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.